INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on May 15, 2023, by INVO Bioscience, Inc. (Nasdaq: INVO), serves as a current report announcing the issuance of a press release regarding financial results for the period ended March 31, 2023. The filing is categorized under Item 2.02 (Results of Operations and Financial Condition).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this 8-K document.
Material Changes
No material changes or comparative financial data are detailed in the text of this filing. The document solely acts as a notification that results for the period ended March 31, 2023, have been released.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2023) for actual financial figures and operational highlights.
- Verify the specific revenue and net loss figures for the quarter ended March 31, 2023, as they are not present in this summary document.
- Check for any updated cash runway or liquidity status mentioned in the full press release.
- Confirm if the company provided any updated fiscal year guidance in the referenced press release.